Needham & Company LLC Forecasts Strong Price Appreciation for Pacira BioSciences (NASDAQ:PCRX) Stock

Pacira BioSciences (NASDAQ:PCRX) had its price objective raised by Needham & Company LLC from $30.00 to $32.00 in a report published on Friday,Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts have also issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $39.00 price target on shares of Pacira BioSciences in a report on Wednesday, December 4th. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their target price for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. Barclays reduced their target price on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a report on Tuesday, November 12th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a report on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $27.22.

Pacira BioSciences Stock Down 5.2 %

Shares of Pacira BioSciences stock opened at $24.05 on Friday. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -11.85 and a beta of 0.80. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. Pacira BioSciences has a 52-week low of $11.16 and a 52-week high of $31.67. The stock has a 50-day simple moving average of $23.16 and a 200-day simple moving average of $18.58.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Sterling Capital Management LLC increased its position in Pacira BioSciences by 779.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock worth $26,000 after buying an additional 1,208 shares during the period. Ancora Advisors LLC bought a new position in Pacira BioSciences in the 4th quarter worth approximately $26,000. Caitlin John LLC increased its position in Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after buying an additional 1,776 shares during the period. Nisa Investment Advisors LLC increased its position in Pacira BioSciences by 495.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after buying an additional 2,749 shares during the period. Finally, PNC Financial Services Group Inc. increased its position in Pacira BioSciences by 16.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after buying an additional 513 shares during the period. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.